-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on TScan Therapeutics, Lowers Price Target to $3

Benzinga·03/07/2025 11:29:41
Listen to the news
Barclays analyst Peter Lawson maintains TScan Therapeutics (NASDAQ:TCRX) with a Overweight and lowers the price target from $14 to $3.